Abstract RF6-01: Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients with high-risk human epidermal growth factor receptor 2-positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy: Interim analysis of DESTINY-Breast05

作者
Sibylle Loibl,Y. H. Park,Z. Shao,C. Huang,C. H. Barrios,J. Abraham,Aleix Prat,N. Niikura,Michael Untch,S. Im,W. Li,H. Li,Y. Wang,H. Yao,S. Kim,Elton George Mathias,J. Petschauer,W. Lu,H. Abdel-Monem,Charles E. Geyer
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:32 (4_Supplement): RF6-01 被引量:1
标识
DOI:10.1158/1557-3265.sabcs25-rf6-01
摘要

Abstract Background: In the phase 3 DESTINY-Breast05 study (NCT04622319) of T-DXd vs. T-DM1 in patients with residual invasive HER2+BC after neoadjuvant treatment (NAT), T-DXd demonstrated statistically significant and clinically meaningful improvement vs T-DM1 in the primary endpoint of invasive disease-free survival (IDFS) and the key secondary endpoint of disease-free survival (DFS; Geyer, ESMO 2025). ∼80% of patients had invasive residual disease in the axillary lymph nodes, 93% received adjuvant radiotherapy (56% concurrent [n = 918]; 37% sequential [n = 605]), and 79%received dual HER2-targeted NAT. Safety was generally manageable with no new safety signals. Here we report additional efficacy and safety data from the DESTINY-Breast05interim analysis. Methods: Patients with residual invasive HER2+ BC following NAT consisting of anti-HER2 therapy and taxane-based chemotherapy and at high risk for recurrence (cT4, N0-3, M0 or cT1-3, N2-3, M0 at presentation prior to NAT, or cT1-3, N0-1, M0, with axillary node-positive disease [ypN1-3] following NAT)were randomized 1:1 to T-DXd 5.4 mg/kg or T-DM1 3.6 mg/kg once every 3 weeks for 14 cycles. All patients receiving adjuvant radiotherapy (RT) were required to have serial chest computed tomography (CT) scans; details to be presented. RT could be administered concurrently with study therapy or prior to initiating study therapy (sequential). Patients receiving sequential therapy had an additional CT scan at the end of the RT. Results: At data cutoff (July 2, 2025), 1635 patients were randomized to T-DXd (n = 818) or T-DM1 (n = 817). Median treatment duration was similar in both arms; more than 70% of patients in both arms received 14 cycles of study therapy. Efficacy results in clinically relevant subgroups will be presented. Adjudicated drug-related interstitial lung disease(ILD) and investigator-reported radiation pneumonitis by timing of adjuvant RT are summarized in the Table. Adjudicated drug-related ILD occurred in 9.6% of patients who received T-DXd; most ILD events were grade 1 or 2, and 0.2% had grade 5 events. No notable differences were observed based on adjuvant RT timing. Incidence of investigator-reported radiation pneumonitis was similar in both arms (31.4% with T-DXd and 30.5% with T-DM1), with no grade ≥3 events and being grade 1. Conclusions: The additional analyses further characterize the positive benefit of T-DXd over T-DM1 in the post-neoadjuvant HER2+ BC residual disease setting, supporting T-DXd as a potential new standard-of-care in this setting. Timing of adjuvant RT did not impact incidence of adjudicated drug-related ILD with T-DXd. Additional results will be presented. Citation Format: S. Loibl, Y. Park, Z. Shao, C. Huang, C. H. Barrios, J. Abraham, A. Prat, N. Niikura, M. Untch, S. Im, W. Li, H. Li, Y. Wang, H. Yao, S. Kim, E. Mathias, J. Petschauer, W. Lu, H. Abdel-Monem, C. E. Geyer Jr.. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients with high-risk human epidermal growth factor receptor 2-positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy: Interim analysis of DESTINY-Breast05 [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr RF6-01.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
传奇3的应助被温凉采纳,获得10
1秒前
1秒前
雪白冷荷完成签到,获得积分10
2秒前
2秒前
滴迪氐媂完成签到 ,获得积分10
3秒前
十三发布了新的文献求助10
3秒前
Yuan88发布了新的文献求助10
3秒前
科研通AI6.2的应助被tszjw168采纳,获得10
3秒前
3秒前
tt完成签到,获得积分10
4秒前
隐无名完成签到,获得积分10
5秒前
含蓄的小鸽子完成签到,获得积分10
5秒前
fantasy的应助被kunkun采纳,获得10
6秒前
科研完成签到,获得积分10
6秒前
Ava的应助被ffff采纳,获得10
6秒前
似宁发布了新的文献求助10
7秒前
Leolr10发布了新的文献求助10
7秒前
机灵毛豆完成签到 ,获得积分10
7秒前
7秒前
淡淡的难破完成签到,获得积分20
8秒前
十三完成签到,获得积分10
8秒前
weifengzhong发布了新的文献求助10
8秒前
8秒前
9秒前
海纳斯发布了新的文献求助10
10秒前
哟邮票完成签到,获得积分10
10秒前
似宁完成签到,获得积分10
10秒前
自信的灵萱完成签到,获得积分10
10秒前
完美世界的应助被科研通管家采纳,获得10
10秒前
彭于晏的应助被科研通管家采纳,获得10
11秒前
搜集达人的应助被科研通管家采纳,获得10
11秒前
小蘑菇的应助被科研通管家采纳,获得10
11秒前
Cecilia23完成签到,获得积分10
11秒前
CodeCraft的应助被科研通管家采纳,获得10
11秒前
隐形曼青的应助被科研通管家采纳,获得10
11秒前
情怀的应助被科研通管家采纳,获得10
11秒前
ding的应助被芯子采纳,获得10
11秒前
FashionBoy的应助被科研通管家采纳,获得10
11秒前
Jasper的应助被科研通管家采纳,获得10
12秒前
科研通AI6.2的应助被科研通管家采纳,获得100
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153668
求助须知:如何正确求助?哪些是违规求助? 9550448
关于积分的说明 21698499
捐赠科研通 7742484
什么是DOI,文献DOI怎么找? 3425564
关于科研通互助平台的介绍 2550698
邀请新用户注册赠送积分活动 2469211